Compare PD & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PD | BBIO |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | 1242 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 14.7B |
| IPO Year | 2019 | 2019 |
| Metric | PD | BBIO |
|---|---|---|
| Price | $13.14 | $75.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 21 |
| Target Price | $17.70 | ★ $76.24 |
| AVG Volume (30 Days) | ★ 2.1M | 1.8M |
| Earning Date | 11-25-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.63 | N/A |
| Revenue | ★ $489,207,000.00 | $353,780,000.00 |
| Revenue This Year | $8.16 | $127.64 |
| Revenue Next Year | $3.88 | $78.38 |
| P/E Ratio | $8.08 | ★ N/A |
| Revenue Growth | 7.01 | ★ 62.46 |
| 52 Week Low | $11.13 | $27.23 |
| 52 Week High | $20.00 | $78.44 |
| Indicator | PD | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 47.27 | 62.87 |
| Support Level | $12.69 | $75.82 |
| Resistance Level | $13.11 | $78.44 |
| Average True Range (ATR) | 0.36 | 2.20 |
| MACD | 0.14 | -0.24 |
| Stochastic Oscillator | 84.08 | 68.91 |
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.